4 天之前 · TOKYO and BOSTON -- February 7, 2025 – Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma”, “MTPC” or “the Company”) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The investment is ...

4 天之前 · Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corpo. Bain Capital, a leading global private ...

1 天前 · Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group Corporation.The investment values the business at approximately $3.3 billion. Through the discovery and development of innovative drugs that address unmet medical needs, MTPC focuses on several priority therapeutic areas ...

2 天之前 · Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

4 天之前 · Following rumblings of a private equity bidding war late last year, Bain Capital has emerged triumphant on its quest to obtain Japanese drugmaker Mitsubishi Tanabe Pharma. Bain is laying out 510 ...

4 天之前 · Bain Capital has placed a $3.3bn bet on a historic shift in Japan’s conservative drugs approval regime by buying a pharmaceutical company founded more than three centuries ago. The US firm on...

4 天之前 · The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion. ... Supported by Bain Capital, Tanabe plans to make ...

1 天前 · Bain Capital on Friday dropped $3.3 billion to acquire Mitsubishi Tanabe Pharma Corporation in a carve-out deal, giving the investment firm access to the Japanese life sciences space.. Tanabe will function independently of its previous parent Mitsubishi Chemical Group Corporation and will continue to work on its priority areas, including vaccines, diabetes and metabolic diseases and central ...

4 天之前 · Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease ...

4 天之前 · TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma”, “MTPC” or “the Company”) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The investment is being led by ...